

## **CORPORATE RELEASE**

Valby, Denmark, March 18, 2026

# Lundbeck held its Annual General Meeting on 18 March 2026 at the company's registered office

H. Lundbeck A/S (Lundbeck) announced today that the report by the Board of Directors was adopted and the annual report was approved at the annual general meeting.

The proposal to distribute a dividend of 36% of the net profit and 30% of net profit adjusted for the impairment loss of the planned divestment of a non-core production site in Italy for the accounting year 2025, corresponding to DKK 1.15 per share, or a total dividend of DKK 1,145 million, was adopted.

The Remuneration Report for 2025 was approved in the advisory vote.

Dorothea Wenzel, Lene Skole-Sørensen, Lars Erik Holmqvist, Jeffrey Berkowitz, Santiago Arroyo, and Jakob Riis and Lars Green were re-elected to the Board of Directors. Rita Balice-Gordon was elected as a new member of the Board of Directors. In advance of the annual general meeting, there had been held elections for employee representatives to the Board of Directors. Kjartan Frisch Herrik and Hossein Armandi were elected as company representatives and Lasse Skibsbye and Camilla Gram Andersson were elected by employees from the Danish subsidiaries in the Lundbeck Group.

The Board of Directors of Lundbeck will hereafter comprise:

- Dorothea Wenzel (Chair)
- Lene Skole-Sørensen (Deputy Chair)
- Lars Erik Holmqvist
- Jeffrey Berkowitz
- Santiago Arroyo
- Jakob Riis
- Lars Green
- Rita Balice-Gordon
- Kjartan Frisch Herrik (employee representative)
- Hossein Armandi (employee representative)
- Lasse Skibsbye (employee representative)
- Camilla Gram Andersson (employee representative)

Immediately after the general meeting, the Board of Directors elected Dorothea Wenzel as Chair and Lene Skole-Sørensen as Deputy Chair of the Board of Directors.

After having elected its Chair and Deputy Chair, the Board of Directors appointed the members of the Audit Committee, the Remuneration and Nomination Committee and the Scientific Committee. Lars Green (Chair), Jeffrey Berkowitz and Jakob Riis were elected as members of the Audit Committee. Dorothea Wenzel (Chair), Lene Skole-Sørensen and Jeffrey Berkowitz were elected as members of the Remuneration and Nomination Committee. Santiago Arroyo (Chair), Lene Skole-Sørensen, Dorothea Wenzel and Rita Balice-Gordon were elected as members of the Scientific Committee.

The general meeting approved the remuneration for the Board of Directors for the year 2026.

PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected as the company's auditor, which will include the task of auditing the company's sustainability reporting.

The proposal to grant the Board of Directors authorization until the next annual general meeting to let the company acquire treasury shares of a total nominal value of up to 10% of the share capital, was adopted. The purchase price for the relevant shares may not deviate by more than 10% from the price quoted on NASDAQ Copenhagen A/S at the time of the acquisition.

The proposal from the Board of Directors to adopt the amended Remuneration Policy for the Board of Directors and the Executive Management introducing a potential increase of the pay-out under the STI-program for the CEO, was adopted.

The Chair of the general meeting was authorized to file for registration of the resolutions passed at the general meeting with the Danish Business Authority.

No other business was on the agenda at the annual general meeting.

## **The Board of Directors**

### Contacts

Jens Høyer  
Vice President, Head of Investor Relations  
[JSHR@lundbeck.com](mailto:JSHR@lundbeck.com)  
+45 30 83 45 01

Anders Crillesen  
Head of Media Relations, Corp. Communication  
[AECE@lundbeck.com](mailto:AECE@lundbeck.com)  
+45 29 79 12 86

## About H. Lundbeck A/S

Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site [www.lundbeck.com](http://www.lundbeck.com) and connect with us via LinkedIn.

### **Safe Harbor/Forward-Looking Statements**

**This corporate release contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe", "anticipate", "expect", "estimate", "intend", "plan", "project", "will be", "will continue", "will result", "could", "may", "might", or any variations of such words or other words with similar meanings. All statements other than statements of historical facts included in this corporate release, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements.**

Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Factors that may affect future results include, among others, interest rate and currency exchange rate fluctuations, delay or failure of development projects, production or distribution problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

The forward-looking statements in this document and in oral presentations made on behalf of Lundbeck speak only as at the date of this document. Lundbeck does not undertake any obligation to update or revise forward-looking statements in this corporate release or oral presentations made on behalf of Lundbeck, nor to confirm such statements to reflect subsequent events or circumstances after the date of the release, presentation or in relation to actual results, unless otherwise required by applicable law or applicable stock exchange regulations.